Skip to main content

IQVIA Holdings Value Stock - Dividend - Research Selection

Iqvia s

ISIN: US46266C1053 , WKN: A2JSPM

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Investors in IQVIA Holdings (NYSE:IQV) have unfortunately lost 29% over the last three years

2024-12-28
Many investors define successful investing as beating the market average over the long term. But if you try your hand...

Fortrea: Turning Around As The Activists Move In

2024-12-26
Fortrea, a recent Labcorp spin-off, is poised for recovery with strong bookings, industry inflection, and activist interest, despite a 46% stock drop in 2024. Read more here.

IQVIA Holdings Inc. stock rises Tuesday, still underperforms market

2024-12-24
IQVIA Holdings Inc. stock rises Tuesday, still underperforms market

Tracking William Nygren's Harris Associates Portfolio - Q3 2024 Update

2024-12-23
Harris Associates' 13F portfolio value rose from $59.08B to $76.62B, with 55 significant securities. Read more about the portfolio's holdings and trades in Q3.

IQVIA Holdings Inc. stock outperforms competitors on strong trading day

2024-12-23
IQVIA Holdings Inc. stock outperforms competitors on strong trading day

IQVIA (IQV) Surges 3.0%: Is This an Indication of Further Gains?

2024-12-23
IQVIA (IQV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Digital Health Tools are Expanding in Scope and Function to Aid Patient Diagnosis, Treatment and Monitoring, Says New Report from The IQVIA Institute

2024-12-23
RESEARCH TRIANGLE PARK, N.C., December 23, 2024--Despite a drop in venture funding for digital health companies over the last two-and-a-half years, digital health products and solutions are expanding in scope and function to aid patient diagnosis, treatment, and monitoring. More solutions are now focused on specific diseases, and their commercial appeal has grown as developers build solutions that bring value back to providers, are more easily integrated with health systems, and embrace innovati

These 4 Measures Indicate That IQVIA Holdings (NYSE:IQV) Is Using Debt Reasonably Well

2024-12-22
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Stephens & Co. Initiates Coverage of IQVIA Holdings (IQV) with Overweight Recommendation

2024-12-21

Lazard Global Equity Select Portfolio Q3 2024 Commentary

2024-12-20
In Q3 2024, the Lazard Global Equity Select Portfolio underperformed its benchmark Index. Click here to read the full commentary.